What Aclosan Treats: Main Uses and Benefits

The primary therapeutic focus for Aclosan is the symptomatic management of Benign Prostatic Hyperplasia (BPH), a condition characterized by periods of heightened symptoms that interfere with daily functioning. The medication is applied across therapeutic domains where additional symptomatic support is needed to manage distress caused by an enlarged prostate.

Aclosan is commonly used to help manage Obstructive Voiding Issues, addressing symptom clusters such as a weak urinary stream, hesitancy, and the feeling of incomplete bladder emptying. Providing support that helps ease this overall symptom burden contributes to improved comfort during symptomatic periods, which may assist with the function of voiding.

Quick Fact: Relief for Obstructive and Irritative LUTS

The medication is considered relevant for easing Irritative Urinary Symptoms, which include increased urinary frequency, sudden urgency, and disruptive nocturia. This symptomatic support assists with maintaining functional stability, which may help to ease the disruptive impact on daily routines.

“The medication is used to provide support that may assist with the function of voiding and ease discomfort during symptomatic periods.”

Aclosan is applied in clinical settings that involve acute or disruptive symptom patterns, which includes providing support that may assist with the process involving ureteral stones or easing discomfort associated with a urological device like a ureteral stent. This symptomatic relief may help patients cope more steadily with these difficult, episodic changes.

---

Indications at a Glance

Aclosan is considered relevant for the management of symptomatic BPH, the addressing of bothersome LUTS, and providing support in contexts involving ureteral stones and discomfort related to ureteral stent placement.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Profile: Who Can and Cannot Use Aclosan?

Aclosan (Tamsulosin Hydrochloride) is a medicine with specific regulatory eligibility requirements defined by official government documents. These rules determine which populations may use the medicine and which are formally excluded.

Populations That Must NOT Use Aclosan (Contraindicated):

Classification	Condition	Restriction
Absolute Exclusion	Hypersensitivity	Known allergy to Tamsulosin or any ingredient in the formulation.
Physiological Risk	Orthostatic Hypotension	A history of severe or clinically significant drop in blood pressure upon standing up.
Organ Function	Severe Hepatic Impairment	The medicine is contraindicated in cases of severe liver dysfunction.

Restricted and Non-Recommended Use:

Official labeling strictly limits use by specific demographics and conditions:

• Gender: The medicine is generally indicated only for the adult male population.
• Age: Use is not indicated or recommended for the pediatric population (children and adolescents).
• Physiological State: The medicine is not indicated for use by pregnant or lactating females.
• Surgical Risk: Use requires caution in patients planning cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).

The official regulatory documents establish specific interaction patterns for Aclosan based on its metabolism and additive pharmacological effects. The primary pharmacokinetic interactions involve the cytochrome P450 enzymes CYP3A4 and CYP2D6. Co-administration with strong inhibitors of either enzyme, such as ketoconazole (CYP3A4) or paroxetine (CYP2D6), is documented to increase the systemic exposure (AUC and Cmax) of Aclosan.

This exposure risk leads to a formal contraindication for strong CYP3A4 inhibitors when administered to patients identified as CYP2D6 poor metabolizers. A second major restriction is the formal contraindication against co-administration with other alpha-adrenergic blocking agents, which is based on the risk of additive vasodilation leading to symptomatic hypotension. Use with PDE5 inhibitors (e.g., sildenafil, tadalafil) also requires caution due to the documented potential for further lowering of blood pressure.

Regarding timing, Aclosan must be administered approximately one-half hour following the same meal each day to ensure consistent absorption and stable plasma levels, as taking the medicine fasted is documented to increase systemic exposure. Cimetidine is noted to increase plasma concentrations by reducing Aclosan’s clearance.

Aclosan functions as an alpha-1 adrenergic receptor antagonist, exerting its pharmacodynamic effects by selectively blocking the binding of endogenous catecholamines, such as norepinephrine, to the alpha-1 (alpha1) receptors.

This antagonistic action is primarily concentrated in the smooth muscle cells of the lower urinary tract, specifically the alpha1A-receptor subtype found in the prostate and bladder neck. Receptor blockade prevents the sympathetic signaling cascade that normally initiates smooth muscle contraction. The intracellular consequence is smooth muscle relaxation, leading to an increase in the diameter of the urinary passage and a subsequent decrease in resistance to outflow.

Aclosan also engages alpha1 receptors located on vascular smooth muscle throughout the periphery. Antagonism at these sites modulates the regulation of vascular tone. The resulting physiological adjustment is vasodilation, which contributes to a reduction in systemic peripheral vascular resistance.

How to Use Aclosan (Tamsulosin) — Official Administration Guidelines

This section outlines the specific administration instructions for Aclosan (Tamsulosin Hydrochloride).

---

Administration Requirements

Instruction Entity	Detail (Strictly Regulatory)
Route of Administration	Oral use (taken by mouth).
Dosage Form	Extended-release capsule or prolonged-release hard capsule.
Starting Dose	0.4 mg once daily.
Maximum Dose	May be increased to 0.8 mg once daily for patients who have not responded to the 0.4 mg dose after 2 to 4 weeks.
Meal Timing	Must be taken approximately 30 minutes following the same meal each day (e.g., after breakfast).

---

Mandatory Preparation and Procedural Steps

1. Swallowing Instructions

The capsule must be swallowed whole with water. It is strictly forbidden to crush, chew, split, or open the capsule. Altering the capsule will interfere with the controlled-release mechanism of the medication.

2. Interruptions and Restarting Therapy

If the administration of Aclosan is discontinued or interrupted for several days, the patient must re-start therapy with the 0.4 mg once-daily dose, regardless of their previous prescribed dosage.

3. Population Use

No dose adjustment is warranted for patients with renal impairment. Aclosan is not indicated for use in the pediatric population (under 18 years of age).

These official instructions define the standardized procedure for using Aclosan, focusing on consistent daily timing relative to a meal and mandatory swallowing requirements to ensure the drug's intended action.

Research Evidence / Overview of Studies

Evaluating Research Focus and Efficacy

The research has explored the drug's effects in the body. Studies evaluated whether blocking a specific receptor subtype was associated with observed clinical outcomes.

Primary Efficacy Trials

This substance's effect was evaluated in a series of double-blind, placebo-controlled trials.

• Sustained Effects: One large-scale trial evaluated whether the drug was associated with sustained effects. The study design followed participants over a 52-week period. The primary endpoint was a comparison of symptom scores between the active drug and placebo groups.
• Time to Observed Effect: The studies' findings included evaluation of the time to observed reduction in pain among participants. This observation was a secondary measure of the study.
• Combination Therapy: Other studies explored whether the combination of the drug with a standard-of-care regimen was associated with changes in patient outcomes across all measured variables.

Safety and Administration Profile

The safety profile was a major focus of clinical development, and studies reported on the incidence and severity of adverse events observed in participants.

Trial Protocols and Concurrent Use

Research also evaluated how the substance was administered during trials and noted potential findings related to concurrent use with other substances.

• Dosing Studies: In the studies, the drug was administered with food to evaluate absorption. Pharmacokinetic analyses evaluated the drug's exposure, including the area under the curve ( AUC) and peak concentration ( C max), when administered with and without food.
• Cautions in Specific Populations: Research has noted a potential interaction between the drug and St. John’s Wort, which was evaluated in participants with chronic conditions. Liver enzyme monitoring was part of the study protocols.

Conclusion of Research

In summary, studies have explored the drug's activity compared to alternative treatment strategies to assess differences in outcomes. Further research is ongoing to refine the understanding of its long-term impact and full therapeutic potential. Studies examined the time to observed relief and whether the drug was associated with a change in quality of life.

Key Studies & References

1. Pharmacokinetics of Aclosan in Healthy Subjects: Effects of Food and Dose Proportionality

Common questions about Aclosan (FAQ)

Q: Is Aclosan considered a first-line or second-line treatment option?

Official documentation for Tamsulosin (Aclosan) primarily focuses on its clinical efficacy and safety data in managing the signs and symptoms of Benign Prostatic Hyperplasia (BPH). Clinical studies have examined symptom reduction themes, but the official regulatory labeling does not explicitly classify the medication as first-line or second-line treatment within clinical practice guidelines.

Q: What is the official recommended general duration of Aclosan treatment?

Official documentation for Aclosan does not specify a maximum duration of use. Clinical data shows that effects can be sustained over a long period, with some studies following patients for a year or longer.

Q: Is it normal to not feel different in the first few days of taking Aclosan?

A lack of immediate change is consistent with the established treatment timeline for Aclosan. Studies indicate that significant symptom improvement often begins within one week of starting therapy. However, the full therapeutic effects of the medication may take up to 2 to 4 weeks to fully develop.

Q: What is the official regulatory guidance on alcohol consumption with Aclosan?

According to official product information, taking Aclosan with alcohol has been associated with a potential for further lowering of blood pressure. This effect may increase the risk of experiencing symptoms such as dizziness or feeling faint, particularly when moving from a sitting or lying position.

Q: Is long-term use of Aclosan associated with any specific safety risks?

Serious safety concerns have been reported, particularly a risk known as Intraoperative Floppy Iris Syndrome (IFIS). This complication has been observed during cataract or glaucoma surgery. Official warnings state that patients must disclose all past and current use of this type of medication to their eye surgeon.

Q: Is Aclosan known to cause significant changes in body weight?

The official documentation lists common adverse reactions for Aclosan, such as dizziness and headache. Weight change is not frequently listed among the common adverse reactions documented in the official labeling.

Q: Does Aclosan's effectiveness vary based on a person's gender or weight, according to studies?

Official regulatory documents indicate that the medicine is generally for use in the adult male population. Furthermore, official instructions do not require or specify any dose adjustments based on a patient's body weight.

Q: Can people with certain autoimmune disorders use Aclosan?

Official product labeling lists specific conditions that are considered contraindications (reasons the drug must not be used). These disorders are not cited as a contraindication, as absolute exclusions are limited to severe hepatic impairment, hypersensitivity, and severe orthostatic hypotension.

Q: Can taking Aclosan cause changes in mood or emotional state?

Specific changes in mood or emotional state are not frequently cited in the primary adverse reaction tables of official regulatory documents. However, effects such as dizziness, headache, and weakness (asthenia) are commonly reported.

Q: Where can I find the official full prescribing information document for Aclosan?

The official full prescribing information is hosted by government drug databases, such as the FDA's Drugs@FDA or the DailyMed database in the United States. These resources contain the complete regulatory label and patient information leaflet.

Q: How long has Aclosan been approved and on the market for public use?

The active ingredient in Aclosan, Tamsulosin Hydrochloride, received its initial approval for medical use in major regulatory jurisdictions, such as the United States, in 1997.

Q: What should be done if someone accidentally misses a dose of Aclosan?

Official guidance indicates that if a single dose is missed, it can be taken as soon as it is remembered. However, if the entire day is missed, the patient should skip the forgotten dose and continue with the next scheduled dose at the usual time. Do not double the dose to make up for a missed one.

Q: Is Aclosan considered a controlled substance in the US or other countries?

No, Tamsulosin (Aclosan) is not categorized as a controlled substance in the United States or other major regulatory jurisdictions. It is classified solely as a prescription-only drug.

Q: Is it possible for Aclosan to become less effective over a long period of use (tolerance)?

Clinical trials extending for a year or longer have examined the long-term use of Tamsulosin. These studies generally show that the improvements in urinary symptoms and flow rates are sustained over the study period.

How to Store and Dispose of Aclosan

The storage and disposal requirements for Aclosan are mandated by regulatory agencies to maintain product integrity and ensure public safety.

Storage Conditions:

Aclosan must be stored at Controlled Room Temperature (typically 20 C to 25 C), with the product kept in its original, tightly closed container to protect it from moisture and light. It is strictly prohibited to freeze Aclosan, and it should not be stored in areas exposed to excessive heat or humidity.

Handling and Child Safety:

To prevent accidental exposure, the medicine must be kept out of the sight and reach of children at all times. Do not use the medicine past the expiration date printed on the packaging.

Official Disposal:

Expired or unused Aclosan should be disposed of using an official drug take-back program. If a take-back program is not available, official guidance instructs patients to mix the medicine with an unappealing substance, seal it in a plastic bag, and place it in the household trash. It must not be flushed down the toilet unless the product is specifically listed as safe for flushing.